{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:50:44Z","timestamp":1791370244636,"version":"4.3.1"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp; Dementia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Anti\u2010amyloid antibody clinical trials with a high proportion of participants reaching treatment\u2010related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double\u2010blind period was likewise associated with clinical benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We pooled ENGAGE and EMERGE (E\/E) aducanumab\u2010treated participants in the amyloid positron emission tomography substudy who continued into the long\u2010term extension \u2264 134\u00a0weeks (continuously treated population) and\/or returned to the EMBARK redosing study 0.7 to 2.5 years after termination of E\/E (treatment gap population). Clinical outcomes were stratified by week 78 TRAC status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>TRAC participants had less clinical decline at week 78, week 134, and EMBARK baseline than non\u2010TRAC participants. Post\u2010TRAC, clinical decline was heterogeneous; approximately two thirds of TRAC participants had annualized decline of\u00a0&lt;\u00a01 point on Clinical Dementia Rating Sum of Boxes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>In these exploratory analyses, week 78 TRAC status was associated with better clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>NCT02484547, NCT02477800, NCT04241068<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.71758","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:03:01Z","timestamp":1791367381000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies"],"prefix":"10.1002","volume":"22","author":[{"given":"Menglan","family":"Pang","sequence":"first","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Brothers","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O'Gorman","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Zabar","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Lasky","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Rubino","sequence":"additional","affiliation":[{"name":"Biogen Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Knopman","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Dyck CH","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER\u2010ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","journal-title":"JAMA"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein S","year":"2022","journal-title":"J Prev Alzheimer's Dis"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman RJ","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.0000000000207438","article-title":"Implications of the approval of Lecanemab for Alzheimer disease patient care: incremental step or paradigm shift?","volume":"101","author":"Knopman DS","year":"2023","journal-title":"Neurology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER\u2010ALZ randomized clinical trial","volume":"79","author":"Shcherbinin S","year":"2022","journal-title":"JAMA Neurol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaneurol.2025.3869","article-title":"Posttreatment amyloid levels and clinical outcomes following donanemab for early symptomatic Alzheimer disease","volume":"82","author":"Lu M","year":"2025","journal-title":"JAMA Neurol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2025.2974","article-title":"Concurrent changes in plasma phosphorylated tau 217, tau PET, and cognition in preclinical Alzheimer disease","volume":"82","author":"Insel PS","year":"2025","journal-title":"JAMA Neurol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12382","article-title":"An insider's perspective on FDA approval of aducanumab","volume":"9","author":"Wang Y","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70997","article-title":"Treatment\u2010related amyloid clearance (TRAC): a framework to characterize patients in the era of anti\u2010amyloid therapies","volume":"21","author":"La Joie R","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti\u2010amyloid monoclonal antibody therapy for Alzheimer's disease: strategies and research directions","volume":"22","author":"Cummings JL","year":"2025","journal-title":"Neurotherapeutics"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack CR","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100458","article-title":"A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease","volume":"13","author":"Chen T","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack CR","year":"2017","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context\u2010of\u2010use from the AMYPAD consortium","volume":"20","author":"Collij LE","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","article-title":"Comparison of amyloid PET measured in centiloid units with neuropathological findings in Alzheimer's disease","volume":"12","author":"Amadoru S","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011214","article-title":"Defining the Lowest Threshold for Amyloid\u2010PET to Predict Future Cognitive Decline and Amyloid Accumulation","volume":"96","author":"Farrell ME","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny J","year":"2016","journal-title":"Nature"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki S","year":"2012","journal-title":"Arch Neurol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","article-title":"A semiautomated method for quantification of F 18 florbetapir PET images","volume":"56","author":"Joshi AD","year":"2015","journal-title":"J Nucl Med"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating partially discordant results in phase 3 studies of aducanumab","volume":"10","author":"Mallinckrodt C","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100202","article-title":"Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease","volume":"12","author":"Burton J","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews JS","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14436","article-title":"Appropriate use of meaningful within\u2010patient change (MWPC) thresholds in Alzheimer's disease","volume":"21","author":"Lansdall CJ","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Temporal dynamics of beta\u2010amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust WJ","year":"2021","journal-title":"Neurology"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71758","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:03:06Z","timestamp":1791367386000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/alz.71758"],"URL":"https:\/\/doi.org\/10.1002\/alz.71758","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71758"}}